Drugs / CMV-TCR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05140187 | Oct 2021 → Dec 2024 | cytomegalovirus infection | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05089838 | Jan 2021 → Oct 2023 | cytomegalovirus infection, disease related to hematopoietic stem cell transplant | Xiao-Jun Huang | Unknown | No outcome recorded |
| Phase 1 | NCT04153279 | Dec 2019 → Nov 2022 | cytomegalovirus infection | Hebei Yanda Ludaopei Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04153279 ↗ |
| Action | Deplete | “The TCR-T cells showed efficient cytotoxicity toward epitope-expressing target cells in vitro.” PMID 36054234 ↗ Sep 2022 |
| Modality | Cell therapy | “T-cell receptor (TCR)-T cell therapy offers a promising option to treat CMV infections.” PMID 36054234 ↗ Sep 2022 |
| Route | Intravenous | “will be intravenously infused” NCT04153279 ↗ |